Journal of Clinical Oncology · 2000 · 96 citations · 64 references
MedicineCancer BiologyOncologyBreast OncologyMolecular OncologyOncogenesBreast Cancer OncologyCancer BiomarkersImmuno-oncology BiomarkersMale Breast CancerTumor AntigensTumor-associated AntigensAndrogen ReceptorsBreast Cancer HistologyBreast Cancer Molecular SubtypesCell Proliferation IndicesMale Breast TumorsMalignant Breast TumorsMonoclonal Antibodies In CancerMyc In Breast Cancer
PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC). PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal carcinoma were retrospectively studied. All patients received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins were immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, and bcl-2 124 monoclonal antibodies (mAbs). Estrogen, progesterone, and androgen receptors were detected using specific mAbs. Cell proliferation was assessed by MIB-1 mAb. RESULTS: In univariate analysis, c-myc, c-erbB-2, and p53 protein overexpression was significantly correlated with prognosis. The median survival was 107 months for c-myc-negative and 52 months for c-myc-positive patients (P =.01), 96 months for c-erbB-2-negative and 39 months for c-erbB-2-positive patients (P =.02), and 100 months for p53-negative and 33 months for p53-positive patients (P =.0008). Tumor histologic grade (P =.01), tumor size (P =.02), patient age at diagnosis (P =.03), and MIB-1 scores (P =.0004) also had prognostic value. In multivariate analysis, only c-erbB-2 and p53 immunoreactivity retained independent prognostic significance. All nine patients who did not express c-erbB-2 and p53 proteins were alive after 58 months, whereas none of the 14 patients expressing both proteins survived at 61 months follow-up (P =.0002). CONCLUSION: Overexpression of c-myc, c-erbB-2, and p53 proteins may be regarded as an additional prognostic factor in MBC. The combination of c-erbB-2 and p53 immunoreactivity can stratify patients into different risk groups.
64
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D. Craig Allred, Jennet Harvey, Melora D. Berardo et al. · PubMed · 1998 · 2.2K citations
Medicine, Cancer Biology, Oncology +16
Neu-Protein Overexpression in Breast Cancer
Marc J. van de Vijver, Johannes L. Peterse, Wolter J. Mooi et al. · New England Journal of Medicine · 1988 · 867 citations
Expression of Cellular Oncogenes in Human Malignancies
Dennis J. Slamon, Jean B. deKernion, Inder M. Verma et al. · Science · 1984 · 833 citations
Medicine, Cancer Biology, Oncology +13